CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod
administered in addition to standard therapy in subjects with active Systemic Lupus
Erythematosus (SLE) disease as defined by SELENA-SLEDAI score ≥10 despite on-going stable
corticosteroid therapy.